Manami Takahashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Manami Takahashi has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Emi Yamazaki
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
4 shared publications - Taku Fujimura
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
4 shared publications - Yoshihide Asano
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
4 shared publications - Yumi Kambayashi
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
4 shared publications - Ryo Amagai
Department of Dermatology Tohoku University Graduate School of Medicine Sendai Japan
3 shared publications - Akihiko Kitamura
Ajinomoto Co., Inc., Kawasaki 210-8681, Japan
2 shared publications
Latest Publications
- 17 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5)
Successful Control of Langer hans Cell Sarcoma in a Super‐Aged Patient Using Intensity‐Modulated Radiotherapy
- 17 March 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (5)
Successful Control of Langer hans Cell Sarcoma in a Super‐Aged Patient Using Intensity‐Modulated Radiotherapy
- 28 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (1) , 140-144
Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration
Immune checkpoint inhibitors (ICIs) have improved melanoma outcomes but can cause severe immune‐related colitis. Infliximab is often used for steroid‐refractory cases, yet its effect on tumor control remains uncertain. We describe three advanced melanoma patients who developed grade 3–4 colitis after nivolumab plus ipilimumab and were treated with infliximab. Although gastrointestinal symptoms improved, all showed rapid disease progression and died within 3–9 months. These cases suggest that infliximab may compromise antitumor immunity in melanoma patients receiving ICIs.
- 28 October 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (1) , 140-144
Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration
Immune checkpoint inhibitors (ICIs) have improved melanoma outcomes but can cause severe immune‐related colitis. Infliximab is often used for steroid‐refractory cases, yet its effect on tumor control remains uncertain. We describe three advanced melanoma patients who developed grade 3–4 colitis after nivolumab plus ipilimumab and were treated with infliximab. Although gastrointestinal symptoms improved, all showed rapid disease progression and died within 3–9 months. These cases suggest that infliximab may compromise antitumor immunity in melanoma patients receiving ICIs.
- 25 March 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6) , 1090-1093
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment
The combination of BRAF and MEK kinase inhibitors is a well‐established treatment for BRAF V600‐mutated advanced melanoma. However, the efficacy of these therapies against less common BRAF mutations, such as BRAF L597, remains unclear. We report two cases of advanced melanoma harboring the BRAF L597 mutation. In the first case, a 77‐year‐old man with metastatic melanoma achieved complete remission following combination therapy with nivolumab and ipilimumab. In the second case, a 50‐year‐old woman with metastatic melanoma exhibited resistance to multiple systemic therapies, including nivolumab, ipilimumab, and targeted therapy with encorafenib and binimetinib. These cases highlight the variable therapeutic responses in melanoma with the BRAF L597 mutation, suggesting that immune checkpoint inhibitors may be a viable first‐line treatment, particularly for patients with a high tumor mutational burden. Further studies are needed to establish optimal treatment strategies for this rare mutation.
- 25 March 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (6) , 1090-1093
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment
The combination of BRAF and MEK kinase inhibitors is a well‐established treatment for BRAF V600‐mutated advanced melanoma. However, the efficacy of these therapies against less common BRAF mutations, such as BRAF L597, remains unclear. We report two cases of advanced melanoma harboring the BRAF L597 mutation. In the first case, a 77‐year‐old man with metastatic melanoma achieved complete remission following combination therapy with nivolumab and ipilimumab. In the second case, a 50‐year‐old woman with metastatic melanoma exhibited resistance to multiple systemic therapies, including nivolumab, ipilimumab, and targeted therapy with encorafenib and binimetinib. These cases highlight the variable therapeutic responses in melanoma with the BRAF L597 mutation, suggesting that immune checkpoint inhibitors may be a viable first‐line treatment, particularly for patients with a high tumor mutational burden. Further studies are needed to establish optimal treatment strategies for this rare mutation.
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis
Mycosis fungoides (MF) is an indolent form of cutaneous T‐cell lymphoma. Its early lesions are important to be distinguished from atopic dermatitis (AD) because of their similar immune microenvironment. We have previously demonstrated that several chemokines are involved in the pathogenesis of advanced MF. Therefore, we sought to comprehensively analyze the changes in the immune environment during the advanced phase of MF by focusing on serum cytokines and chemokines and to identify potential biomarkers for the early detection of the transition to the advanced phase of MF. Sera from 11 cases of advanced‐stage MF, 16 cases of mild AD (median EASI score = 5.75), 16 cases of severe AD (median EASI score = 28.1), and 21 healthy volunteers were analyzed using the Bio‐Plex 40 multiplex immunoassay system. The results revealed significant increases in immunosuppressive macrophage‐related factors (IL‐4, MIF, CCL3) in MF patients compared to those with AD and healthy controls. In contrast, IL‐2, CCL1, CCL7, CCL21, CCL25, and CCL26 were significantly increased in severe AD patients compared to MF patients and healthy controls. Our findings suggest that several chemokines and cytokines contribute to an immunosuppressive environment favorable for tumor growth, distinguishing MF from AD. Moreover, T‐cell proliferation and migration factors, which are mainly involved in maintaining inflammation, are elevated in severe AD compared to MF. In addition to elucidating the differences in the pathogenesis of these diseases, these factors may be important in the differential diagnosis of early MF and AD. Further studies are warranted to confirm these findings.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessComprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis
Mycosis fungoides (MF) is an indolent form of cutaneous T‐cell lymphoma. Its early lesions are important to be distinguished from atopic dermatitis (AD) because of their similar immune microenvironment. We have previously demonstrated that several chemokines are involved in the pathogenesis of advanced MF. Therefore, we sought to comprehensively analyze the changes in the immune environment during the advanced phase of MF by focusing on serum cytokines and chemokines and to identify potential biomarkers for the early detection of the transition to the advanced phase of MF. Sera from 11 cases of advanced‐stage MF, 16 cases of mild AD (median EASI score = 5.75), 16 cases of severe AD (median EASI score = 28.1), and 21 healthy volunteers were analyzed using the Bio‐Plex 40 multiplex immunoassay system. The results revealed significant increases in immunosuppressive macrophage‐related factors (IL‐4, MIF, CCL3) in MF patients compared to those with AD and healthy controls. In contrast, IL‐2, CCL1, CCL7, CCL21, CCL25, and CCL26 were significantly increased in severe AD patients compared to MF patients and healthy controls. Our findings suggest that several chemokines and cytokines contribute to an immunosuppressive environment favorable for tumor growth, distinguishing MF from AD. Moreover, T‐cell proliferation and migration factors, which are mainly involved in maintaining inflammation, are elevated in severe AD compared to MF. In addition to elucidating the differences in the pathogenesis of these diseases, these factors may be important in the differential diagnosis of early MF and AD. Further studies are warranted to confirm these findings.
- Open Access
- 25 November 2022
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 86 (12) , 2040
Spontaneous Coronary Artery Dissection at 3 Years After Vertebral Artery Dissection Without Relationship to Pregnancy
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 25 November 2022
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 86 (12) , 2040
Open AccessSpontaneous Coronary Artery Dissection at 3 Years After Vertebral Artery Dissection Without Relationship to Pregnancy
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 22 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (43)
Neurodegenerative processes accelerated by protein malnutrition and decelerated by essential amino acids in a tauopathy mouse model
Intake of specific seven essential amino acids affects the pathology of the brain.
- 22 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (43)
Open AccessNeurodegenerative processes accelerated by protein malnutrition and decelerated by essential amino acids in a tauopathy mouse model
Intake of specific seven essential amino acids affects the pathology of the brain.
- Open Access
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Tau‐induced brain atrophy and neuroinflammation accelerated by low‐protein diet and decelerated by selected essential amino acids in a murine model of tauopathies
Background: Nutritional epidemiology has implicated dietary protein intake in senile dementias. However, mechanistic links of protein and amino acids to age‐related neurodegenerative conditions remain unclear. Here, we tested the hypothesis that dietary intake of protein and amino acids could affect neuronal functions and survival in a mouse model of tauopathies, which develops tau pathologies leading to progressive brain atrophy with aging.Methods: Non‐transgenic (nTg) and tauopathy model (rTg4510) mice were fed a normal protein diet (NPD) or low protein diet (LPD) from 3 months of age, and brain volume and tau pathologies were measured at 6.5 months of age by MRI and PET, respectively. These imaging assays were also applied to NPD‐ and LPD‐fed mice treated with essential amino acids (EAAs), seven essential amino acids (EAAs), which are primarily composed of leucine, phenylalanine, and lysine with high fluxes into the brain and contain minimum levels of tryptophan, an origin of inflammation‐related kynurenine pathways. Moreover, we performed gene expression profiling of the cortical tissues collected from these mice.Results: LPD profoundly accelerated the brain atrophy in rTg4510 mice relative to NPD. EAA supplementation to rTg4510 mice markedly suppressed cortical volume reductions in both LPD‐ and NPD‐fed rTg4510. LPD and EAA did not overtly alter PET‐detectable tau depositions uncorrected for atrophy‐induced partial volume effects, raising a possibility of decreased tau burdens in each of surviving neurons to some extent. Gene expression profiling demonstrated neuroinflammatory changes and neuronal dysfunctions in rTg4510 mice, which were worsened by LPD and attenuated by EAAs. Notably, kynurenine levels were elevated by LPD, and this alteration was reversed by EEAs, presumably by competition between EEAs and kynurenine on the entry into the brain.Conclusion: Our findings highlight the critical roles of specific EEAs in the protection of neurons against tau‐induced toxicity and neuroinflammation.
- 7 December 2020
- Published by Wiley in Alzheimer's & Dementia
- Vol. 16 (S2)
Open AccessTau‐induced brain atrophy and neuroinflammation accelerated by low‐protein diet and decelerated by selected essential amino acids in a murine model of tauopathies
Background: Nutritional epidemiology has implicated dietary protein intake in senile dementias. However, mechanistic links of protein and amino acids to age‐related neurodegenerative conditions remain unclear. Here, we tested the hypothesis that dietary intake of protein and amino acids could affect neuronal functions and survival in a mouse model of tauopathies, which develops tau pathologies leading to progressive brain atrophy with aging.Methods: Non‐transgenic (nTg) and tauopathy model (rTg4510) mice were fed a normal protein diet (NPD) or low protein diet (LPD) from 3 months of age, and brain volume and tau pathologies were measured at 6.5 months of age by MRI and PET, respectively. These imaging assays were also applied to NPD‐ and LPD‐fed mice treated with essential amino acids (EAAs), seven essential amino acids (EAAs), which are primarily composed of leucine, phenylalanine, and lysine with high fluxes into the brain and contain minimum levels of tryptophan, an origin of inflammation‐related kynurenine pathways. Moreover, we performed gene expression profiling of the cortical tissues collected from these mice.Results: LPD profoundly accelerated the brain atrophy in rTg4510 mice relative to NPD. EAA supplementation to rTg4510 mice markedly suppressed cortical volume reductions in both LPD‐ and NPD‐fed rTg4510. LPD and EAA did not overtly alter PET‐detectable tau depositions uncorrected for atrophy‐induced partial volume effects, raising a possibility of decreased tau burdens in each of surviving neurons to some extent. Gene expression profiling demonstrated neuroinflammatory changes and neuronal dysfunctions in rTg4510 mice, which were worsened by LPD and attenuated by EAAs. Notably, kynurenine levels were elevated by LPD, and this alteration was reversed by EEAs, presumably by competition between EEAs and kynurenine on the entry into the brain.Conclusion: Our findings highlight the critical roles of specific EEAs in the protection of neurons against tau‐induced toxicity and neuroinflammation.
- Open Access
- 1 December 2020
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 59 (23) , 3039-3044
Coexistence of Marfan-like Connective Tissue Disease with Morphologic Left Ventricular Non-compaction
We treated a man with co-incident Marfan-like connective tissue disease with morphologic left ventricular non-compaction (LVNC). He underwent valve-sparing aortic root replacement because of aortic root dilation at 43 years old. Pathological findings of the aorta revealed cystic medio-necrosis, consistent with Marfan syndrome. He developed congestive heart failure caused by LVNC at 47 years old. His daughter had scoliosis, and he had several physical characteristics suggestive of Marfan syndrome. We herein report a rare case of a patient who had Marfan-like connective disease with an LVNC appearance.
- 1 December 2020
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 59 (23) , 3039-3044
Open AccessCoexistence of Marfan-like Connective Tissue Disease with Morphologic Left Ventricular Non-compaction
We treated a man with co-incident Marfan-like connective tissue disease with morphologic left ventricular non-compaction (LVNC). He underwent valve-sparing aortic root replacement because of aortic root dilation at 43 years old. Pathological findings of the aorta revealed cystic medio-necrosis, consistent with Marfan syndrome. He developed congestive heart failure caused by LVNC at 47 years old. His daughter had scoliosis, and he had several physical characteristics suggestive of Marfan syndrome. We herein report a rare case of a patient who had Marfan-like connective disease with an LVNC appearance.
- 1 August 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (15) , 1891-1894
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity
- 1 August 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (15) , 1891-1894
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity